Combination effect of doxorubicin and HIF inhibitor on MCF-7 CD44+/CD24- subpopulation cells in hypoxic condition
Open Access
- 1 January 2022
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 58
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcomaAutophagy, 2012
- HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breastBMC Cancer, 2012
- The Role of Breast Cancer Stem Cells in Metastasis and Therapeutic ImplicationsThe American Journal of Pathology, 2011
- Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1αCancer Chemotherapy and Pharmacology, 2010
- FM19G11, a New Hypoxia-inducible Factor (HIF) Modulator, Affects Stem Cell Differentiation StatusJournal of Biological Chemistry, 2010
- Evidence for a stem cell hierarchy in the adult human breastJournal of Cell Biology, 2007
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2003